p53 Mutations in Nasal Natural Killer/T-Cell Lymphoma from Mexico-Reference-Cited by-同舟云学术

p53 Mutations in Nasal Natural Killer/T-Cell Lymphoma from Mexico

Published:2001-12 Issue:6 Volume:159 Page:2095-2105
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Quintanilla-Martinez Leticia,Kremer Marcus,Keller Gisela,Nathrath Michaela,Gamboa-Dominguez Armando,Meneses Abelardo,Luna-Contreras Lourdes,Cabras Antonello,Hoefler Heinz,Mohar Alejandro,Fend Falko

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference53 articles.

1. Nasal and nasal-type NK/T cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus;Jaffe;Histopathology,1995

2. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology;Jaffe;Am J Surg Pathol,1996

3. Nonnasal lymphomas expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm;Chan;Blood,1997

4. Immunophenotypic analysis of non-Hodgkin's lymphomas in Chinese: a study of 75 cases in Hong Kong;Ng;Pathology,1986

5. Clinicopathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight year period;Ho;Int J Cancer,1984

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Master regulator: p53’s pivotal role in steering NK-cell tumor patrol;Frontiers in Immunology;2024-08-09

2. Extranodal natural killer/T-cell lymphoma with tonsil involvement: a case report;BMC Oral Health;2024-07-30

3. Extranodal NK/T-Cell Lymphoma Predominantly Composed of Anaplastic Cells;American Journal of Surgical Pathology;2023-11-20

4. Contribution of the Epstein-Barr virus to the oncogenesis of mature T-cell lymphoproliferative neoplasms;Frontiers in Oncology;2023-09-14

5. How molecular advances may improve the diagnosis and management of PTCL patients;Frontiers in Oncology;2023-06-23